Profile data is unavailable for this security.
About the company
Jubilant Pharmova Limited is an India-based integrated pharmaceutical company. The Company's segments include Pharmaceuticals, Contract Research and Development Services and Proprietary Novel Drugs. The Pharmaceuticals segment, through wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of active pharmaceutical ingredients (APIs), solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six manufacturing facilities in India, United States and Canada and a network of approximately 48 radio pharmacies in the United States. The Contract Research and Development Services segment provides drug discovery and development services as well as clinical data software and service solutions. The Proprietary Novel Drugs segment is a patient-focused biopharmaceutical business working to address unmet medical needs in oncology and autoimmune diseases.
- Revenue in INR (TTM)66.22bn
- Net income in INR378.60m
- Incorporated1978
- Employees1.03k
- LocationJubilant Pharmova Ltd1A, Sector 16ANOIDA 201301IndiaIND
- Phone+91 1 204361000
- Fax+91 1 204234881
- Websitehttps://www.jubl.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blue Jet Healthcare Ltd | -100.00bn | -100.00bn | 65.76bn | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 5.49 | -- | -11.88 | -- | -- | -- |
| Sun Pharma Advanced Research Co Ltd | 1.07bn | -3.63bn | 71.49bn | 407.00 | -- | -- | -- | 67.02 | -11.22 | -11.22 | 3.29 | -- | -- | -- | -- | 2,621,133.00 | -- | -59.13 | -- | -119.29 | 75.21 | 79.70 | -340.66 | -116.46 | -- | -400.34 | -- | -- | 73.98 | 25.00 | -9.43 | -- | -13.96 | -- |
| Marksans Pharma Ltd | 21.03bn | 3.17bn | 72.30bn | 1.40k | 22.64 | -- | 18.68 | 3.44 | 7.05 | 7.05 | 46.71 | -- | -- | -- | -- | 15,024,090.00 | -- | 14.78 | -- | 19.58 | 51.88 | 50.16 | 15.21 | 13.01 | -- | 44.45 | -- | 5.49 | 24.23 | 15.20 | 44.29 | 51.89 | 6.61 | 58.49 |
| F D C Ltd | 19.16bn | 2.90bn | 73.54bn | 6.37k | 25.63 | -- | 22.38 | 3.84 | 17.63 | 17.63 | 116.59 | -- | -- | -- | -- | 3,006,457.00 | -- | 11.68 | -- | 13.29 | 65.72 | 62.03 | 15.11 | 15.85 | -- | 70.61 | -- | 1.22 | 16.74 | 10.49 | -10.34 | 2.26 | 25.03 | -- |
| Strides Pharma Science Ltd | 39.53bn | -1.52bn | 76.37bn | 2.85k | -- | -- | 129.10 | 1.93 | -16.88 | -10.96 | 436.72 | -- | -- | -- | -- | 13,871,790.00 | -- | -0.9448 | -- | -1.59 | 58.90 | 49.75 | -4.37 | -2.19 | -- | 0.9061 | -- | -- | 20.13 | 5.33 | 51.93 | -- | -25.10 | -5.59 |
| Procter & Gamble Health Ltd | 11.69bn | 2.14bn | 78.75bn | 1.41k | 36.82 | -- | 32.71 | 6.74 | 128.85 | 128.85 | 703.49 | -- | -- | -- | -- | 8,305,331.00 | -- | -- | -- | -- | 70.45 | -- | 18.31 | -- | -- | 400.33 | -- | -- | 10.34 | -- | 19.19 | -- | -- | -- |
| Wockhardt Ltd | 27.76bn | -5.01bn | 83.53bn | 2.74k | -- | -- | -- | 3.01 | -34.79 | -34.79 | 192.79 | -- | -- | -- | -- | 10,131,390.00 | -- | -4.12 | -- | -7.34 | 57.60 | 53.98 | -19.16 | -10.98 | -- | -0.1981 | -- | -- | -17.93 | -7.60 | -129.10 | -- | -7.43 | -- |
| Neuland Laboratories Ltd. | 15.81bn | 3.17bn | 95.68bn | 1.57k | 30.18 | -- | 25.60 | 6.05 | 247.14 | 247.14 | 1,232.07 | -- | -- | -- | -- | 10,048,590.00 | -- | 5.69 | -- | 7.95 | 51.76 | 43.56 | 20.06 | 8.07 | -- | 28.54 | -- | 8.27 | 25.25 | 17.62 | 156.21 | 68.43 | -13.12 | -- |
| Caplin Point Laboratories Ltd | 16.30bn | 4.38bn | 98.63bn | 777.00 | 22.66 | -- | 20.15 | 6.05 | 57.33 | 57.33 | 213.53 | -- | -- | -- | -- | 20,980,180.00 | -- | 21.04 | -- | 24.25 | 56.48 | 52.84 | 27.08 | 25.02 | -- | 845.56 | -- | 9.37 | 15.54 | 22.13 | 25.49 | 21.05 | 31.87 | 17.61 |
| Granules India Ltd | 45.26bn | 3.95bn | 99.58bn | 3.65k | 25.18 | -- | 16.65 | 2.20 | 16.32 | 16.32 | 186.88 | -- | -- | -- | -- | 12,400,240.00 | -- | 11.15 | -- | 16.55 | 51.94 | 49.35 | 8.73 | 12.39 | -- | 6.53 | -- | 10.08 | 19.84 | 21.67 | 25.16 | 31.26 | -1.66 | 8.45 |
| Glenmark Life Sciences Ltd | 22.83bn | 4.71bn | 102.97bn | 1.82k | 21.90 | 4.41 | 19.64 | 4.51 | 38.38 | 38.38 | 186.08 | 190.35 | 0.8224 | 1.58 | 2.90 | -- | 16.96 | 18.28 | 20.43 | 30.03 | 56.11 | 53.40 | 20.62 | 20.23 | 2.85 | 401.55 | 0.0073 | -- | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Jubilant Pharmova Ltd | 66.22bn | 378.60m | 110.51bn | 1.03k | 287.99 | -- | 18.85 | 1.67 | 2.42 | 2.42 | 415.43 | -- | -- | -- | -- | 64,045,440.00 | -- | 3.95 | -- | 4.78 | 67.64 | 66.57 | 0.5133 | 6.27 | -- | 1.36 | -- | 18.52 | 2.47 | -3.63 | -114.73 | -- | 10.74 | 10.76 |
| Eris Lifesciences Ltd | 18.61bn | 3.86bn | 118.82bn | 3.55k | 30.79 | -- | 21.89 | 6.38 | 28.36 | 28.36 | 136.57 | -- | -- | -- | -- | 5,245,254.00 | -- | 17.62 | -- | 20.12 | 82.02 | 80.57 | 20.36 | 27.34 | -- | 7.94 | -- | -- | 25.10 | 14.52 | -5.90 | 5.38 | 101.87 | -- |
| Astrazeneca Pharma India Ltd | 11.97bn | 1.39bn | 132.86bn | 947.00 | 95.38 | -- | 85.87 | 11.10 | 55.72 | 55.72 | 478.78 | -- | -- | -- | -- | 12,640,230.00 | -- | 10.51 | -- | 18.10 | 59.93 | 58.05 | 11.64 | 9.11 | -- | 132.84 | -- | 11.82 | 24.50 | 11.89 | 61.19 | 30.82 | 6.29 | -- |
| Concord Biotech Ltd | 9.71bn | 3.05bn | 162.49bn | -- | 54.01 | -- | 45.31 | 16.74 | 28.76 | 28.76 | 92.74 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 79.70 | -- | 31.38 | -- | -- | -- | -- | -- | 19.67 | -- | 37.25 | -- | -- | -- |
Data as of May 10 2024. Currency figures normalised to Jubilant Pharmova Ltd's reporting currency: Indian Rupee INR
18.73%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| East Bridge Capital Management L.P.as of 30 Sep 2023 | 11.94m | 7.50% |
| Norges Bank Investment Managementas of 30 Sep 2023 | 6.30m | 3.96% |
| The Vanguard Group, Inc.as of 05 Apr 2024 | 3.11m | 1.96% |
| quant Money Managers Ltd.as of 31 Mar 2024 | 2.79m | 1.75% |
| Abakkus Asset Manager LLPas of 30 Sep 2023 | 1.91m | 1.20% |
| Dimensional Fund Advisors LPas of 04 Apr 2024 | 1.65m | 1.04% |
| BlackRock Fund Advisorsas of 04 Apr 2024 | 1.09m | 0.68% |
| Nippon Life India Asset Management Ltd. (Invt Mgmt)as of 31 Mar 2024 | 528.24k | 0.33% |
| BlackRock Advisors (UK) Ltd.as of 02 Apr 2024 | 293.78k | 0.18% |
| HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Mar 2024 | 215.01k | 0.14% |
More ▼
Data from 31 Dec 2023 - 02 May 2024Source: FactSet Research Systems Inc.
